CNS Pharmaceuticals (NASDAQ: CNSP), a biotechnology company specializing in the development of novel treatments for brain tumors, received positive feedback from the U.S. Food and Drug Administration (“FDA”) for its Pre-IND (Investigational New Drug) meeting proposal to use Berubicin, a lyophilized drug product, in Phase II clinical trials. The FDA indicated, in response to CNS … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces Positive FDA Pre-IND Guidance for Berubicin”
CNS Pharmaceuticals (NASDAQ: CNSP) is a biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors. Its lead candidate Berubicin is for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as pancreatic and ovarian cancers, and lymphomas. The company entered … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Starts Presentation at 12th Annual LD Micro Main Event”
Related Press Release CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for … Continue reading “NetworkNewsAudio – CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial”
